Loading clinical trials...

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia

NCT01106716•KAI Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption
•pain score at least 4 on 11-point numerical rating scale (0-10)
•stable doses of analgesic medications for at least 1 month"

Exclusion Criteria

•diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption
•pain score at least 4 on 11-point numerical rating scale (0-10)
•stable doses of analgesic medications for at least 1 month"

Locations (1)

Sydney, New South Wales, Australia

Key Dates

Start Date

March 1, 2009

Primary Completion Date

March 1, 2010

Completion Date

April 1, 2010

Last Updated

September 2, 2025

Enrollment

ACTUAL participants

Conditions

Postherpetic Neuralgia

Interventions

Placebo

DRUG

KAI-1678

DRUG

Lidocaine

DRUG

The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

NCT07000409

Postherpetic NeuralgiaChronic Pain+3 more

View study

RECRUITINGNA

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

NCT06896994

Postherpetic Neuralgia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

Inclusion Criteria

Exclusion Criteria

The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

Relationship Between Serum Vitamin D Levels and Postherpetic Neuralgia.

Dorsal Root Ganglion Stimulation in Postherpetic Neuropathy

Predictors of Success After Intercostal Nerve Radiofrequency Treatment for Intercostal Neuralgia

Esketamine Combined With PRF of DRG for Postherpetic Neuralgia